Drug Target Review

AUGUST 28, 2024

What are the main challenges currently faced in the treatment of chronic liver diseases, and how does Resolution Therapeutics aim to address these challenges? Dr Brass has published over 85 peer reviewed articles and more than 200 abstracts, primarily in the field of hepatology, in both the areas of clinical and basic science research.

Therapies 116

Therapies Disease Engineering Medical Schools 116

The Pharma Data

NOVEMBER 18, 2021

A review by the external Data Monitoring Committee (eDMC) determined that this effect was related to treatment with the combination of ISL08507; the greatest decreases were seen in the arms of the study receiving the highest doses of MK-8507 (200 mg and 400 mg). The company has notified investigators and paused development of MK-8507.

Clinical Trials 52

Clinical Trials Treatment Trials RNA 52

The Pharma Data

OCTOBER 25, 2021

At 48 weeks, both trials met their primary efficacity endpoint of chance of actors with HIV-1 RNA situations ? Doravirine is approved for the treatment of grown-ups with HIV-1 in combination with other antiretrovirals, as a single agent (PIFELTRO) and a element of a single- tablet authority (DELSTRIGO; DOR/ 3TC/ TDF).

Treatment 52

Treatment Trials RNA Clinical Trials 52

The Pharma Data

MARCH 8, 2021

At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data.”. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission, as well as SARS-CoV-1 and MERS. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

OCTOBER 27, 2021

– This Clinical Study is the First from Merck and Gilead’s Collaboration to Develop Potential Long-Acting HIV Treatment Options –. Joan Butterton, vice chairman, global clinical development, contagious conditions, Merck Research Laboratories. The primary endpoint is the proportion of study actors with HIV-1 RNA viral cargo ?

Treatment 52

Treatment Clinical Trials Clinical Development Trials 52

The Pharma Data

JULY 12, 2021

It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “If View the full release here: [link]. “It

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

The Pharma Data

SEPTEMBER 1, 2021

Molnupiravir (MK-4482/EIDD-2801) is an investigational, orally administered form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. in collaboration with Ridgeback Biotherapeutics.

Laboratories 52

Laboratories Clinical Trials Virus Trials 52